Gubra (GUBRA) Partnership summary

Opening remarks and agenda

• Announcement of a transformative partnership and license agreement for the GUBamy Amylin Program (GUB014295), marking AbbVie's entry into the obesity field, with key executives present to address questions.

• Analyst and investor presentation scheduled, hosted by Gubra's CEO, CSO, and CFO.

Objectives of the partnership

• Exclusive global license agreement with AbbVie to develop and commercialize GUBamy (GUB014295), aiming to accelerate its path to market and address unmet needs in obesity care.

• The deal is structured to maximize the potential of GUBamy in the obesity market and foster long-term growth.

Partner introductions and roles

• AbbVie selected for its strong development, commercial, and financial capabilities, and will lead global development and commercialization of GUBamy.

• Gubra specializes in preclinical research and peptide-based drug discovery, focusing on early-stage development.

• Gubra’s CEO, CSO, and CFO are leading the transition and ongoing collaboration.